Mode
Text Size
Log in / Sign up
N/A N=90 Diagnostic

Comparison of Serum C Type Natriuretic Peptide Levels Between Polycystic Ovary Syndrome Patients and Healthy Women

Polycystic Ovary Syndrome · c Type Natriuretic Peptide · Menstrual Irregularity · Hyperandrogenism

Enrolled (actual)
90
Serious AEs
Results posted
Nov 2021
Primary outcome: Primary: Serum CNP Levels of PCOS and Healthy Participants — 110; 57 pg/ml — p=0.004

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
C type natriuretic peptide (Diagnostic_test)
Age
Adult · 18+ yrs
Sex
Female
Sponsor
Near East University, Turkey
Primary completion
Sep 2020

Outcome Measures

OutcomeResultp-value
PRIMARY
Serum CNP Levels of PCOS and Healthy Participants
110; 57 0.004 sig
PRIMARY
Roc Curve of CNP
0.706 0.004 sig
SECONDARY
Comparison of FSH and LH of PCOS and Healthy Women
4.7; 4.97; 4.23; 5.36 0.171
SECONDARY
Serum Estradiol Levels of PCOS and Healthy Women
31; 36.5 0.306
SECONDARY
Serum Tiroid Stimulating Hormone of PCOS and Healthy Women
1.61; 1.47 0.795
SECONDARY
Serum Prolactin Levels of PCOS and Healthy Women
17.21; 16.80 0.852
SECONDARY
Serum Androstenedione Levels of PCOS and Healthy Women
148.89; 84.66 <0.001 sig
SECONDARY
Serum Dehydroepiandrosterone Sulfate (DHEAS) Levels of PCOS and Healthy Women
304.55; 299.95 0.277
SECONDARY
Serum Total Testosterone Levels of PCOS and Healthy Women
1.38; 0.92 0.006 sig
SECONDARY
Serum Free Testosterone Levels of PCOS and Healthy Women
1.71; 1.12 <0.001 sig
SECONDARY
Serum Sex Hormone Binding Globulin Levels of PCOS and Healthy Women
30.4; 59.4 0.014 sig
SECONDARY
Free Androgen Index of Participants
4.39; 1.55 <0.001 sig
SECONDARY
Serum Glucose, Total Cholesterol and Triglycerides Levels of Participants
164; 171; 78; 77; 88.5; 89 0.947
SECONDARY
High Density Lipoprotein and Low Density Lipoprotein Levels of Participants
53.82; 62.15; 98.50; 92.92 0.114
SECONDARY
Serum Insulin Levels of Participants
7.10; 7.10 0.713
SECONDARY
Homeostatic Model Assessment of Insulin Resistance of Participants
1.50; 1.45 0.886

Summary

Recent studies have shown that C natriuretic peptide is produced from granulosa cells, increasing cumulative guanosine monophosphate (cGMP) production by affecting cumulus cells through natriuretic peptide receptors. It is suggested that produced cGMP maintains the transport of oocytes via the gap junctions and leads to a continuous increase in cyclic adenosine monophosphate (cAMP) levels in the oocyte. An important role of increased internal cAMP levels in the oocyte is shown to suppress meiotic progression. Deoxyribonucleic acid studies in animals have shown that expression of the natriuretic peptide precursor increases during the periovulatory period and shows that this increase decreases rapidly after luteinizing hormone / human chorionic gonadotropin (hCG) stimulation.Human studies have shown that after ovulation induction, the CNP level in follicular fluid decreases following ovulatory dose of hCG.Polycystic ovary syndrome (PCOS) is the most common endocrine disease in the reproductive period, characterized by hyperandrogenism, oligo-anovulation, and polycystic ovarian morphology on ultrasonography, and in an animal study investigating the relationship between CNP and PCOS, serum CNP levels were increased in polycystic ovary syndrome.CNP serum level is thought to show differences between healthy women and women with polycystic ovary syndrome.

Eligibility Criteria

Inclusion Criteria

  • PCOS defined according to Rotterdam criteria
  • Healthy normal menstruating women

Exclusion Criteria

  • Diabetes mellitus
  • Cardiavascular disease
  • Renal disease
  • Any drug usage
  • Smoking
  • Pregnancy
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT04006171). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search